Ack1 Mediated AKT/PKB Tyrosine 176 Phosphorylation Regulates Its Activation

The AKT/PKB kinase is a key signaling component of one of the most frequently activated pathways in cancer and is a major target of cancer drug development. Most studies have focused on its activation by Receptor Tyrosine Kinase (RTK) mediated Phosphatidylinositol-3-OH kinase (PI3K) activation or loss of Phosphatase and Tensin homolog (PTEN). We have uncovered that growth factors binding to RTKs lead to activation of a non-receptor tyrosine kinase, Ack1 (also known as ACK or TNK2), which directly phosphorylates AKT at an evolutionarily conserved tyrosine 176 in the kinase domain. Tyr176-phosphorylated AKT localizes to the plasma membrane and promotes Thr308/Ser473-phosphorylation leading to AKT activation. Mice expressing activated Ack1 specifically in the prostate exhibit AKT Tyr176-phosphorylation and develop murine prostatic intraepithelial neoplasia (mPINs). Further, expression levels of Tyr176-phosphorylated-AKT and Tyr284-phosphorylated-Ack1 were positively correlated with the severity of disease progression, and inversely correlated with the survival of breast cancer patients. Thus, RTK/Ack1/AKT pathway provides a novel target for drug discovery.

[1]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[2]  D. Tindall,et al.  Dynamic FoxO transcription factors , 2007, Journal of Cell Science.

[3]  T. Ono,et al.  Infrequent Genetic Alterations of the PTEN/MMAC1 Gene in Japanese Patients with Primary Cancers of the Breast, Lung, Pancreas, Kidney, and Ovary , 1997, Japanese journal of cancer research : Gann.

[4]  Activated AKT/PKB signaling in C. elegans uncouples temporally distinct outputs of DAF-2/insulin-like signaling , 2006, BMC Developmental Biology.

[5]  J. Testa,et al.  Activation of AKT kinases in cancer: implications for therapeutic targeting. , 2005, Advances in cancer research.

[6]  J. Mohler,et al.  Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation , 2007, Proceedings of the National Academy of Sciences.

[7]  L. Cantley,et al.  PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.

[8]  N. Mahajan,et al.  An SH2 Domain-dependent, Phosphotyrosine-independent Interaction between Vav1 and the Mer Receptor Tyrosine Kinase , 2003, Journal of Biological Chemistry.

[9]  Huan Yang,et al.  The Akt/PKB pathway: molecular target for cancer drug discovery , 2005, Oncogene.

[10]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[11]  Jerónimo Bravo,et al.  Binding of the PX domain of p47phox to phosphatidylinositol 3,4‐bisphosphate and phosphatidic acid is masked by an intramolecular interaction , 2002, The EMBO journal.

[12]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[13]  F. McCormick,et al.  Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. , 1998, Science.

[14]  W. Miller,et al.  Biochemical Properties of the Cdc42-associated Tyrosine Kinase ACK1 , 2003, Journal of Biological Chemistry.

[15]  D. Coppola,et al.  Effect of Ack1 tyrosine kinase inhibitor on ligand‐independent androgen receptor activity , 2010, The Prostate.

[16]  L. Beckett,et al.  Incidence, mechanism and prognostic value of activated AKT in pancreas cancer , 2003, British Journal of Cancer.

[17]  Hoyun Lee,et al.  The Akt isoforms are present at distinct subcellular locations. , 2010, American journal of physiology. Cell physiology.

[18]  J. Carpten,et al.  PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation , 2008, British journal of haematology.

[19]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[20]  R. Pearson,et al.  Direct Identification of Tyrosine 474 as a Regulatory Phosphorylation Site for the Akt Protein Kinase* 210 , 2002, The Journal of Biological Chemistry.

[21]  Yiling Lu,et al.  AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.

[22]  B. Burgering,et al.  Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction , 1995, Nature.

[23]  S. Powers,et al.  Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  F. McCormick,et al.  Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. , 1997, Science.

[25]  Y. Qiu,et al.  Regulation of Akt/PKB Activation by Tyrosine Phosphorylation* , 2001, The Journal of Biological Chemistry.

[26]  Hailing Cheng,et al.  The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation , 2006, Proceedings of the National Academy of Sciences.

[27]  Carmen Blanco-Aparicio,et al.  PTEN, more than the AKT pathway. , 2007, Carcinogenesis.

[28]  M. Tada,et al.  Differential Mechanisms of Constitutive Akt/PKB Activation and Its Influence on Gene Expression in Pancreatic Cancer Cells , 2002, Japanese journal of cancer research : Gann.

[29]  L. Lim,et al.  A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42 , 1993, Nature.

[30]  F. Liu,et al.  PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. , 2005, American journal of physiology. Endocrinology and metabolism.

[31]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[32]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[33]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[34]  T. Kataoka,et al.  Stimulation of Ras Guanine Nucleotide Exchange Activity of Ras-GRF1/CDC25Mm upon Tyrosine Phosphorylation by the Cdc42-regulated Kinase ACK1* , 2000, Journal of Biological Chemistry.

[35]  E. Greer,et al.  FOXO transcription factors at the interface between longevity and tumor suppression , 2005, Oncogene.

[36]  J. Schlessinger,et al.  Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Pinder,et al.  The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome , 2004, The Journal of pathology.

[38]  Terry L. Smith,et al.  Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers , 2004, Clinical Cancer Research.

[39]  D. Bar-Sagi,et al.  Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos , 2007, Nature Cell Biology.

[40]  P. Cohen,et al.  Mechanism of activation of protein kinase B by insulin and IGF‐1. , 1996, The EMBO journal.

[41]  James L Mohler,et al.  Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. , 2005, Cancer research.

[42]  Wannian Yang,et al.  Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation. , 2007, Molecular biology of the cell.

[43]  Andrius Kazlauskas,et al.  The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase , 1995, Cell.

[44]  J E Paciga,et al.  AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. , 2001, The American journal of pathology.

[45]  S. Bose,et al.  The Akt pathway in human breast cancer: a tissue-array-based analysis , 2006, Modern Pathology.